Literature DB >> 28381542

Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium.

Jennifer Ose1,2, Elizabeth M Poole3, Helena Schock1, Matti Lehtinen4, Alan A Arslan5,6, Anne Zeleniuch-Jacquotte6, Kala Visvanathan7, Kathy Helzlsouer7, Julie E Buring8,9, I-Min Lee8,9, Anne Tjønneland10, Laure Dossus11, Antonia Trichopoulou12,13, Giovanna Masala14, N Charlotte Onland-Moret15, Elisabete Weiderpass16,17,18,19, Eric J Duell20, Annika Idahl21, Ruth C Travis22, Sabina Rinaldi23, Melissa A Merritt24, Britton Trabert25, Nicolas Wentzensen25, Shelley S Tworoger3,9, Rudolf Kaaks1, Renée T Fortner26.   

Abstract

Invasive epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The etiology of EOC remains elusive; however, experimental and epidemiologic data suggest a role for hormone-related exposures in ovarian carcinogenesis and risk factor differences by histologic phenotypes and developmental pathways. Research on prediagnosis androgen concentrations and EOC risk has yielded inconclusive results, and analyses incorporating EOC subtypes are sparse. We conducted a pooled analysis of 7 nested case-control studies in the Ovarian Cancer Cohort Consortium to investigate the association between pre-diagnosis circulating androgens [testosterone, free testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEAS)], sex hormone binding globulin (SHBG), and EOC risk by tumor characteristics (i.e., histology, grade, and stage). The final study population included 1,331 EOC cases and 3,017 matched controls. Multivariable conditional logistic regression was used to assess risk associations in pooled individual data. Testosterone was positively associated with EOC risk (all subtypes combined, ORlog2 = 1.12; 95% confidence interval 1.02-1.24); other endogenous androgens and SHBG were not associated with overall risk. Higher concentrations of testosterone and androstenedione associated with an increased risk in endometrioid and mucinous tumors [e.g., testosterone, endometrioid tumors, ORlog2 = 1.40 (1.03-1.91)], but not serous or clear cell. An inverse association was observed between androstenedione and high grade serous tumors [ORlog2 = 0.76 (0.60-0.96)]. Our analyses provide further evidence for a role of hormone-related pathways in EOC risk, with differences in associations between androgens and histologic subtypes of EOC. Cancer Res; 77(14); 3951-60. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28381542      PMCID: PMC5512110          DOI: 10.1158/0008-5472.CAN-16-3322

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Louise A Brinton; Garnet L Anderson; Ruth M Pfeiffer; Roni T Falk; Howard D Strickler; Sarunas Sliesoraitis; Lewis H Kuller; Margery L Gass; Barbara J Fuhrman; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-05       Impact factor: 4.254

2.  Clinical significance of hormonal receptor status of malignant ovarian tumors.

Authors:  I G Tkalia; L I Vorobyova; V S Svintsitsky; S V Nespryadko; I V Goncharuk; N Y Lukyanova; V F Chekhun
Journal:  Exp Oncol       Date:  2014-06

3.  Circulating levels of sex steroid hormones and risk of ovarian cancer.

Authors:  Annekatrin Lukanova; Eva Lundin; Arslan Akhmedkhanov; Andrea Micheli; Sabina Rinaldi; Anne Zeleniuch-Jacquotte; Per Lenner; Paola Muti; Carine Biessy; Vittorio Krogh; Franco Berrino; Göran Hallmans; Elio Riboli; Rudolf Kaaks; Paolo Toniolo
Journal:  Int J Cancer       Date:  2003-05-01       Impact factor: 7.396

4.  Plasma androgen concentrations and risk of incident ovarian cancer.

Authors:  Shelley S Tworoger; I-Min Lee; Julie E Buring; Susan E Hankinson
Journal:  Am J Epidemiol       Date:  2007-11-03       Impact factor: 4.897

5.  Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation.

Authors:  E G Silva; C Tornos; M Deavers; K Kaisman; K Gray; D Gershenson
Journal:  Gynecol Oncol       Date:  1998-11       Impact factor: 5.482

Review 6.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

Review 7.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

Review 8.  Adrenal Hyperandrogenism and Polycystic Ovary Syndrome.

Authors:  Manuel Luque-Ramírez; Héctor F Escobar-Morreale
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

9.  Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study.

Authors:  Rebecca E James; Annekatrin Lukanova; Laure Dossus; Susen Becker; Sabina Rinaldi; Anne Tjønneland; Anja Olsen; Kim Overvad; Sylvie Mesrine; Pierre Engel; Françoise Clavel-Chapelon; Jenny Chang-Claude; Alina Vrieling; Heiner Boeing; Madlen Schütze; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Domenico Palli; Vittorio Krogh; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; Laudina Rodríguez; Genevieve Buckland; Maria-José Sánchez; Pilar Amiano; Eva Ardanaz; Bas Bueno-de-Mesquita; Martine M Ros; Carla H van Gils; Petra H Peeters; Kay-Tee Khaw; Nick Wareham; Timothy J Key; Naomi E Allen; Isabelle Romieu; Afshan Siddiq; David Cox; Elio Riboli; Rudolf Kaaks
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-02

10.  Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).

Authors:  Sabina Rinaldi; Laure Dossus; Annekatrin Lukanova; Petra H M Peeters; Naomi E Allen; Timothy Key; Sheila Bingham; Kay-Tee Khaw; Dimitrios Trichopoulos; Antonia Trichopoulou; Eleni Oikonomou; Guillem Pera; Nerea Larrañaga; Carmen Martinez-Garcia; Eva Ardanaz; J Ramón Quirós; María-José Tormo; Anne Tjønneland; Anja Olsen; Kim Overvad; Jenny Chang-Claude; Jakob Linseisen; Mandy Schulz; Heiner Boeing; Carla H van Gils; Bas H Bueno-de-Mesquita; Valeria Pala; Domenico Palli; Salvatore Panico; Rosario Tumino; Paolo Vineis; Françoise Clavel-Chapelon; Sylvie Mesrine; Marie-Christine Boutron-Ruault; Eva Lundin; Asa Agren; Göran Berglund; Jonas Manjer; Merethe Kumle; Eiliv Lund; Nadia Slimani; Rodolfo Saracci; Elio Riboli; Rudolf Kaaks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-01       Impact factor: 4.254

View more
  23 in total

1.  Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.

Authors:  T Huang; S S Tworoger; W C Willett; M J Stampfer; B A Rosner
Journal:  Ann Oncol       Date:  2019-02-01       Impact factor: 32.976

2.  Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.

Authors:  Holly R Harris; Ana Babic; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Elisa V Bandera; Nicolas Wentzensen; Joanne Kotsopoulos; Steven A Narod; Catherine M Phelan; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Anna H Wu; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

3.  Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity.

Authors:  Clara Bodelon; J Keith Killian; Joshua N Sampson; William F Anderson; Rayna Matsuno; Louise A Brinton; Jolanta Lissowska; Michael S Anglesio; David D L Bowtell; Jennifer A Doherty; Susan J Ramus; Aline Talhouk; Mark E Sherman; Nicolas Wentzensen
Journal:  Clin Cancer Res       Date:  2019-05-29       Impact factor: 12.531

4.  Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.

Authors:  James Yarmolinsky; Caroline J Bull; Emma E Vincent; Jamie Robinson; Axel Walther; George Davey Smith; Sarah J Lewis; Caroline L Relton; Richard M Martin
Journal:  JAMA       Date:  2020-02-18       Impact factor: 56.272

5.  Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies.

Authors:  Francesmary Modugno; Zhuxuan Fu; Susan J Jordan; Aocs Group; Jenny Chang-Claude; Renée T Fortner; Marc T Goodman; Kirsten B Moysich; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Bo Qin; Rebecca Sutphen; John R McLaughlin; Usha Menon; Susan J Ramus; Simon A Gayther; Aleksandra Gentry-Maharaj; Chloe Karpinskyj; Celeste L Pearce; Anna H Wu; Harvey A Risch; Penelope M Webb
Journal:  Eur J Epidemiol       Date:  2020-09-21       Impact factor: 8.082

6.  Exposure of human fallopian tube epithelium to elevated testosterone results in alteration of cilia gene expression and beating.

Authors:  Tia Jackson-Bey; José Colina; Brett C Isenberg; Jonathan Coppeta; Margrit Urbanek; J Julie Kim; Teresa K Woodruff; Joanna E Burdette; Angela Russo
Journal:  Hum Reprod       Date:  2020-09-01       Impact factor: 6.918

7.  Urinary PGE-M Levels and Risk of Ovarian Cancer.

Authors:  Mollie E Barnard; Alicia Beeghly-Fadiel; Ginger L Milne; Eftitan Y Akam; Andrew T Chan; A Heather Eliassen; Bernard A Rosner; Xiao-Ou Shu; Kathryn L Terry; Yong-Bing Xiang; Wei Zheng; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-06       Impact factor: 4.254

8.  The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).

Authors:  Britton Trabert; Shelley S Tworoger; Katie M O'Brien; Mary K Townsend; Renée T Fortner; Edwin S Iversen; Patricia Hartge; Emily White; Pilar Amiano; Alan A Arslan; Leslie Bernstein; Louise A Brinton; Julie E Buring; Laure Dossus; Gary E Fraser; Mia M Gaudet; Graham G Giles; Inger T Gram; Holly R Harris; Judith Hoffman Bolton; Annika Idahl; Michael E Jones; Rudolf Kaaks; Victoria A Kirsh; Synnove F Knutsen; Marina Kvaskoff; James V Lacey; I-Min Lee; Roger L Milne; N Charlotte Onland-Moret; Kim Overvad; Alpa V Patel; Ulrike Peters; Jenny N Poynter; Elio Riboli; Kim Robien; Thomas E Rohan; Dale P Sandler; Catherine Schairer; Leo J Schouten; Veronica W Setiawan; Anthony J Swerdlow; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Kala Visvanathan; Lynne R Wilkens; Alicja Wolk; Anne Zeleniuch-Jacquotte; Nicolas Wentzensen
Journal:  Cancer Res       Date:  2020-01-13       Impact factor: 12.701

9.  Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.

Authors:  Renée T Fortner; Elizabeth M Poole; Nicolas A Wentzensen; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Tess V Clendenen; Agnès Fournier; Gary Fraser; Susan M Gapstur; Mia M Gaudet; Graham G Giles; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Rudolf Kaaks; Victoria A Kirsh; Synnove Knutsen; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; Roger L Milne; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Maria-José Sánchez; Catherine Schairer; Leo J Schouten; Anne Tjonneland; Mary K Townsend; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Paolo Vineis; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2019-01-14       Impact factor: 7.396

10.  Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium.

Authors:  Shelley S Tworoger; Leo J Schouten; Renée T Fortner; Megan S Rice; Synnove F Knutsen; Michael J Orlich; Kala Visvanathan; Alpa V Patel; Mia M Gaudet; Anne Tjønneland; Marina Kvaskoff; Rudolf Kaaks; Antonia Trichopolou; Valeria Pala; N Charlotte Onland-Moret; Inger T Gram; Pilar Amiano; Annika Idahl; Naomi E Allen; Elisabete Weiderpass; Jenny N Poynter; Kim Robien; Graham G Giles; Roger L Milne; Veronica W Setiawan; Melissa A Merritt; Piet A van den Brandt; Anne Zeleniuch-Jacquotte; Alan A Arslan; Katie M O'Brien; Dale P Sandler; Alicja Wolk; Niclas Håkansson; Holly R Harris; Britton Trabert; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-07-30       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.